This inventor holds 8 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignees: Merck Sharp + Dohme Corp., Merck + Co., Inc., Other. Active years: 2009-2014.
Company Filing History:
6 out of 2,405 
1 out of 4,770 
1 out of 834,307 Years Active: 2009-2014
Title: Christopher Hamblett: Innovator in Pharmaceutical Chemistry
Introduction
Christopher Hamblett is a notable inventor based in Boston, MA (US), recognized for his contributions to pharmaceutical chemistry. He holds a total of 8 patents, showcasing his innovative approach to developing compounds that address significant medical challenges.
Latest Patents
Among his latest inventions are spirocyclic compounds, which represent a novel class of substituted compounds capable of inhibiting histone deacetylase. These compounds are designed to selectively induce terminal differentiation and arrest the growth of neoplastic cells, making them valuable in treating tumors characterized by such cell proliferation. Additionally, these compounds may aid in the prevention and treatment of TRX-mediated diseases, including autoimmune, allergic, and inflammatory conditions, as well as neurodegenerative diseases affecting the central nervous system. Another significant patent involves silylated piperidine derivatives, which selectively attenuate the production of Aβ(1-42) and are intended for the treatment of Alzheimer's disease and related conditions.
Career Highlights
Christopher has worked with prominent organizations, including Merck Sharp & Dohme Corp., where he has contributed to groundbreaking research and development in the pharmaceutical field. His work has significantly impacted the understanding and treatment of various diseases.
Collaborations
Throughout his career, Christopher has collaborated with notable colleagues such as Thomas Allen Miller and Joey Lee Methot, enhancing the scope and impact of his research.
Conclusion
Christopher Hamblett's innovative work in pharmaceutical chemistry continues to pave the way for new treatments and therapies. His patents reflect a commitment to addressing critical health issues through scientific advancement.